A Randomized, Parallel-group, Placebo-controlled, Double-blind Phase 1/2a Study in Healthy HIV Uninfected Adults to Assess Safety/Tolerability and Immunogenicity of 2 Different Prime/Boost Regimens: Priming With Tetravalent Ad26.Mos4.HIV and Boosting With Tetravalent Ad26.Mos4.HIV and Either Clade C gp140 Plus Adjuvant OR a Combination of Mosaic and Clade C gp140 Plus Adjuvant

Trial Profile

A Randomized, Parallel-group, Placebo-controlled, Double-blind Phase 1/2a Study in Healthy HIV Uninfected Adults to Assess Safety/Tolerability and Immunogenicity of 2 Different Prime/Boost Regimens: Priming With Tetravalent Ad26.Mos4.HIV and Boosting With Tetravalent Ad26.Mos4.HIV and Either Clade C gp140 Plus Adjuvant OR a Combination of Mosaic and Clade C gp140 Plus Adjuvant

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Oct 2017

At a glance

  • Drugs Ad26 Mos4 HIV (Primary) ; HIV clade C gp140 vaccine (Primary) ; HIV mosaic gp140 vaccine (Primary)
  • Indications HIV infections
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms IPCAVD-012
  • Sponsors Janssen
  • Most Recent Events

    • 14 Aug 2017 Planned End Date changed from 28 Dec 2018 to 12 Jan 2019.
    • 21 Apr 2017 Planned End Date changed from 1 Nov 2018 to 25 Dec 2018.
    • 21 Apr 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top